MannKind Corporation (MNKD)

Market Cap	1.09B
Revenue (ttm)	297.60M
Net Income (ttm)	30.12M
Shares Out	303.93M
EPS (ttm)	0.10
PE Ratio	34.52
Forward PE	17.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,307,425
Open	3.740
Previous Close	3.740
Day's Range	3.550 - 3.770
52-Week Range	3.550 - 7.630
Beta	1.01
Analysts	Buy
Price Target	9.75 (+172.35%)
Earnings Date	Aug 6, 2025

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipelin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 28, 2004
• Employees: 407
• Stock Exchange: NASDAQ
• Ticker Symbol: MNKD
• Website: https://www.mannkindcorp.com

Analyst Summary

According to 4 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price target is $9.75, which is an increase of 172.35% from the latest price.

Price Target

$9.75

(172.35% upside)

Analyst Consensus: Buy